A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to analyze the therapeutic effect of adjuvant Licartin therapy after resection.Patients receiving curative resection (R0) were randomized to postoperative Licartin group and no Licartin group. The time to recurrence ,the overall survival as well as the incidence of complications after therapy was observed to confirm the role of adjuvant therapy of Licartin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

1. Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues

2. Karnofsky Performance Score performance over 60

3. The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy.

4. The liver function is of grade A or B in Child-Pugh classification.

5. Patients give consent to the test.

Exclusion Criteria:

1. Negative expression of HAb18G/CD147 in the HCC tissues

2. Allergic history to biologic products(Licartin)

3. Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l.

4. Severed disease of the heart, lung, kidney, brain and blood system.

5. Other severed disease might affect the trial .

6. Patients would not sign the consent to the trial.